Registration Now Open for NPE2024: The Plastics Show
12.9.2023 19:34:00 EEST | Business Wire | Press release
The Plastics Industry Association (PLASTICS) announced today that NPE2024: The Plastics Show registrations are now open through May 2024. NPE2024 will be the most impactful trade show of the year for all plastics industry sectors in the U.S. and globally, with more than 55,000 attendees expected.
Every three years, NPE offers the plastics industry a global platform to highlight innovation across a show floor with more than 1.1 million net square feet of exhibit space at the Orange County Convention Center in Orlando, Fla. Matt Seaholm, President and CEO of PLASTICS, highlighted that NPE2024 will return bigger and better than ever, “We look forward to welcoming our industry back to NPE2024: The Plastics Show next May. The plastic industry serves a critical and sustainable role in modern life; this show will be a testament to that.”
“With sustainability at the center of everything produced at the show, attendees will witness new technologies and significant education opportunities to push us toward a more circular economy and help our industry continue to grow,” said Seaholm.
NPE2024 returns, with the theme Made for You, where attendees are front and center of all experiences happening at the show. The event, held May 6-10, 2024, will offer opportunities for everyone in the industry, even those just starting their career. Some notable experiences at NPE2024 include:
- Six technology zones with 2,000+ exhibitors showcasing their latest products and services
- More than 100 speaker presentations on trending topics that foster innovation, drive circularity and exemplify collaboration
- The brand-new NPE Circularity Hub where attendees will experience the plastics circular economy, from raw materials to go-to market consumer products
- Influential women in the plastics industry will share their success stories with those attending the Women in Plastics Breakfast
- More than 355 first-time exhibitors bringing to NPE2024 new products and perspectives
- The inaugural NPE Opening Night Party featuring the band Pop Rocks, games, food and drinks
NPE2024 attendees will gain exclusive access to the entire plastics supply chain, including machinery and equipment, raw materials, recycling and sustainability, automation and robotics, 3D and 4D printing, inspection, design, and more. NPE exhibitors service vital markets such as automotive, consumer products, recycling, packaging, medical, and building and construction.
Important dates to remember if planning on attending NPE2024:
- Attendee registration for NPE2024 opens on Tuesday, September 12, 2023
- Registration for the hotel room block also begins on Tuesday, September 12, 2023
- NPE2024 event dates are May 6-10, 2024, at the Orange County Convention Center in Orlando, Fla.
Tickets for NPE2024 range from $100 - $600; prices vary depending on early bird, advanced and on-site sales. Add-ons to the NPE Opening Night Party, Women in Plastics Breakfast, Seminarios Latinoamericanos, and 3D Printing for Plastic Processors are also available on a first-come, first-served basis, inquire for details.
“NPE2024 is at the forefront of the plastics future. If you want to further your career, grow your company or keep up with new trends and solutions, NPE2024 is where you need to be in May 2024. We encourage you to register today and start planning and customizing your experience as we continue to reveal all the exciting things happening at the event,” concluded Steve London, NPE2024 Committee Chair.
For more information about NPE2024: The Plastics Show and to register, visit: NPE.org.
The Plastics Industry Association (PLASTICS) is the only organization that supports the entire plastics supply chain, including Equipment Suppliers, Material Suppliers, Processors, and Recyclers, representing over one million workers in our $548 billion U.S. industry. PLASTICS advances the priorities of our members who are dedicated to investing in technologies that improve capabilities and advances in recycling and sustainability and providing essential products that allow for the protection and safety of our lives. Since 1937, PLASTICS has been working to make its members, and the seventh largest U.S. manufacturing industry, more globally competitive while supporting circularity through educational initiatives, industry-leading insights and events, convening opportunities and policy advocacy, including the largest plastics trade show in the Americas, NPE2024: The Plastics Show.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911029303/en/
Contact information
Elizabeth Domenech pr@npe.org
Camille Gallo cgallo@plasticsindustry.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom